Yet, patients with consistently high levels of NKG2D ligands and an impaired NKG2D pathway in immune cells might benefit from therapeutic approaches aimed at reducing ligand expression on tumor cells and on other nontransformed cells, or at recovering normal levels of NKG2D expression on immune cells. Here, KLRK1 is linked to neoplasm.